At BlueDil International, we are entering a new chapter—one that reflects our commitment to innovation, strategic growth and leadership excellence. We are proud to announce a transition in our executive team as Sylvain Forget, our founder and long-standing leader, passes the baton to Leonardo Calzetti, who will be the new CEO.
Since the birth of BlueDil International, Sylvain Forget has played a pivotal role in shaping the organization’s identity and driving its success. His vision and dedication have been instrumental in establishing BlueDil as a trusted partner for pharmaceutical companies and startups navigating the complex European orphan drug landscape.
While stepping down as CEO, Sylvain remains deeply involved with the company as Co-Founder and Senior Partner France, where he will continue to contribute to BlueDil International’s strategic direction and long-term success.
Leonardo Calzetti steps into leadership
Taking on the role of CEO is Leonardo Calzetti, a seasoned executive with decades of experience in Business Development and Strategic Marketing. His strategic vision, dedication and extensive background in the rare and severe diseases sector will be pivotal to lead BlueDil International into its next phase.
Leonardo has been a key part of BlueDil International’s journey since 2021, serving as a Co-Founding Director. Additionally, he is also the founder of Rare Insight Consulting, where he has successfully supported pharmaceutical companies and startups in the European orphan drug field.
Before joining BlueDil, Leonardo held leadership positions in major global pharmaceutical organizations, such as Chiesi, where he took on the role of Head of Global Rare Diseases Franchise, and as the Italian affiliate of Swedish Orphan Biovitrum (Sobi), where he oversaw its development and its operations in Greece and Malta.
A future built on innovation and collaboration
As we move forward, our mission remains unchanged: to provide unparalleled insights and support within the rare and severe diseases world. With this leadership transition, we are confident that BlueDil International will continue to thrive, strengthen its partnerships and make a meaningful impact on global healthcare.